Position in AKBA
as of Mar 31, 2026
· filed Apr 13, 2026
Position Value
$57,155
-$45,758 QoQ
Shares Held
41,119
+45.4% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AKBA Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026E Fund Management Co., Ltd. holds $3,498,956 across 9 Drug Manufacturers - Specialty & Generic names. AKBA ranks #9 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALKS |
Alkermes plc.
|
20,920 | $739,731 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
1,071 | $635,081 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
4,489 | $591,380 | |
| 4 | ZTS |
Zoetis Inc.
|
4,188 | $495,063 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
44,532 | $423,944 | |
| 6 | VTRS |
Viatris Inc
|
27,545 | $372,132 | |
| 7 | IRWD |
Ironwood Pharmaceuticals Inc
|
27,230 | $95,577 | |
| 8 | EBS |
Emergent BioSolutions Inc.
|
10,710 | $88,893 |
All Filings in AKBA
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $57,155 | 41,119 | Shares | Sole | 2026-04-13 | |
| 2025-06-30 | $102,913 | 28,273 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $37,077 | 19,311 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $24,160 | 12,716 | Shares | Sole | 2025-02-07 | |
| 2022-03-31 | $25,309 | 35,250 | Shares | Sole | 2022-05-12 | |
| 2021-12-31 | $55,137 | 24,397 | Shares | Sole | 2022-02-11 | |
| 2021-09-30 | $106,914 | 37,123 | Shares | Sole | 2021-11-12 | |
| 2021-03-31 | $130,017 | 38,410 | Shares | Sole | 2021-05-13 | |
| No filing history on record for this holder in this stock. | ||||||